SEARCH

SEARCH BY CITATION

References

  • 1
    Balch CM, Milton GW, Cascinelli N, Sim FH. Elective lymph node dissection: pros and cons. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma. 2nd ed. Philadelphia: JB Lippincott, 1992: 34566.
  • 2
    Bieß B, Bröcker E-B, Drepper H, Klein M, Lippold A, Peters A. Should elective lymph node dissection be used for treatment of primary melanoma? J Cancer Res Clin Oncol 1989; 115: 4703.
  • 3
    Binder M, Pehamberger H, Steiner A, Wolff K. Elective regional lymph node dissection in malignant melanoma. Eur J Cancer 1990; 26: 8713.
  • 4
    Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM, Tuttle MS. Malignant melanoma of the skin: I. The association of the tumor depth and type, and patient sex, age, and site with survival. Cancer 1983; 52: 133041.
  • 5
    McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection. Surg Gynecol Obstet 1985; 161: 57580.
  • 6
    Crowley NJ, Seigler HF. The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma. Cancer 1990; 66: 25227.
  • 7
    Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong S-J. Prophylactic lymph node dissection in clinical Stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 1982; 69: 10811.
  • 8
    Reintgen DS, Cox EB, McCarthy KS, Vollmer RT, Seigler HF. Efficacy of elective lymph node dissection in patients with intermediate thickness melanoma. Ann Surg 1983; 198: 37985.
  • 9
    Sim FH, Taylor WT, Pritchard DJ, Soule EH. Lymphadenectomy in management of Stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986; 61: 679705.
  • 10
    Veronesi U, Adamus J, Bandiera DC, Brennhovd IO, Caceres E, Cascinelli N, et al. Inefficacy of immediate node dissection in Stage I melanoma of the limbs. N Engl J Med 1977; 297: 62730.
  • 11
    Balch CM. The Role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988; 6: 16372.
  • 12
    Cady B. “Prophylactic” lymph node dissection in melanoma: does it help? J Clin Oncol 1988; 6: 24.
  • 13
    Soong S-J. A computerized mathematical model and scoring system for predicting outcome in patients with localized melanoma. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma. 2nd ed. Philadelphia: JB Lippincott, 1992: 20012.
  • 14
    Clark WH Jr, Elder DE, DuPont G IV, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in Stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81: 18931904.
  • 15
    Day C, Lew RA. Malignant melanoma prognostic factors: VII. elective lymph node dissection. J Dermatol Surg Oncol 1985; 11: 2339.
  • 16
    HermanekP, SobinLH, editors. UICC TNM classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992: 99101.
  • 17
    Balch CM, Urist MM, Maddox WA, Milton GW, McCarthy WH. Management of regional metastatic melanoma. In: BalchCM, MiltonGW, editors. Cutaneous melanoma. 1st ed. Philadelphia: JB Lippincott, 1985: 93130.
  • 18
    Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 9028.
  • 19
    Balch CM, Soong S-J, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: BalchCM, HoughtonAN, MiltonGW, SoberAJ, SoongS-J, editors. Cutaneous melanoma. 2nd ed. Philadelphia: JB Lippincott, 1992: 16599.
  • 20
    Garbe C, Büttner P, Bertz J, Burg G, d'Hoerdt B, Drepper H, et al. Die Prognose des primären malignen Melanoms: eine multizentrische Studie an 5093 Patienten. In: OrfanosCE, GarbeC, editors. Das maligne Melanom der Haut: Neue Erkenntnisse zur Epidemiologie, Diagnostik, experimentellen Forschung, Therapie und Nachsorge. München: Zuckschwerdt, 1990: 4159.
  • 21
    Breslow A. Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. In: AckermanAB, editor. Pathology of malignant melanoma. New York: Masson Publishing, 1982: 122.
  • 22
    Cascinelli N, Morabito A, Bufalino R, Van der Esch EP, Preda F, Vaglini M, et al. Prognosis of Stage I melanoma of the skin. Cancer 1980; 26: 7339.
  • 23
    Cascinelli N, Vaglini M, Bufalino R, Morabito A. BANS: a cutaneous region with no prognostic significance in patients with melanoma. Cancer 1986; 57: 4414.
  • 24
    Cascinelli N, Vaglini M, Nava M, Santinami M, Marolda R, Rovini D, et al. Prognosis of skin melanoma with regional node metastases (Stage II). J Surg Oncol 1984; 25: 2407.
  • 25
    Day CL Jr, Mihm MC Jr, Lew RA, Harris MN, Kopf AW, Fitzpatrick TB, et al. Prognostic factors for patients with clinical Stage I melanoma of intermediate thickness (1.51–3.99 mm): a conceptuel model for tumor growth and metastasis. Ann Surg 1982; 195: 3543.
  • 26
    Drepper H, Bieß B, Lippold A, Padberg G, Wiebelt H. Prätherapeutische Risikoabschätzung beim malignen Melanom. In: OrfanosCE, GarbeC, editors. Das maligne Melanom der Haut: Neue Erkenntnisse zur Epidemiologie, Diagnostik, experimentellen Forschung, Therapie und Nachsorge. München: Zuckschwerdt, 1990: 3240.
  • 27
    Drepper H, Bieß B, Hofherr B, Hundeiker M, Lippold A, Otto F, et al. The prognosis of melanoma patients in Stage III (UICC): prospective long-term study on 286 patients of the Fachklinik Hornheide. Cancer 1993; 71: 123946.
  • 28
    Drzewiecki KT, Andersen PK. Survival with malignant melanoma: a regression analysis of prognostic factors. Cancer 1982; 49: 24149.
  • 29
    Drzewiecki KT, Frydman H, Andersen PK, Poulsen H, Ladefoged C, Vibe P. Malignant melanoma: changing trends in factors influencing metastasis free survival from 1964 to 1982. Cancer 1990; 65: 3626.
  • 30
    Johnson OK, Emrich LJ, Karakousis CP, Rao U, Greco WR. Comparison of prognostic factors for survival and recurrence in malignant melanoma of the skin: clinical Stage I. Cancer 1985; 55: 110717.
  • 31
    Karakousis CP, Emrich LJ, Rao U. Tumor thickness and prognosis in clinical Stage I malignant melanoma. Cancer 1989; 64: 14326.
  • 32
    Kopf AW, Gross DF, Rogers GS, Rigel DS, Hellmann LJ, Levenstein M, et al. Prognostic index for malignant melanoma. Cancer 1987; 59: 123641.
  • 33
    McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous Stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497502.
  • 34
    McGovern VJ, Shaw HM, Milton GW, McCarthy WH. Ulceration and prognosis in cutaneous malignant melanoma. Histopathogy 1982; 6: 399407.
  • 35
    Rogers GS, Kopf AW, Rigel DS, Levenstein ML, Friedman RJ, Harris MN, et al. Influence of anatomic location on prognosis of malignant melanoma: attempt to verify the BANS model. J Am Acad Dermatol 1986; 15: 2317.
  • 36
    Schmoeckel C, Bockelbrink A, Bockelbrink H, Routsis J, Braun-Falco O. Low- and high risk malignant melanoma: I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol 1983; 19: 22735.
  • 37
    Shaw HM, Balch CM, Soong S-J, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 1985; 17: 2714.
  • 38
    Sober AJ. Prognostic factors for cutaneous melanoma. Devel Oncol 1984; 25: 12642.
  • 39
    Sondergaard K. Depth of invasion and tumor thickness in primary cutaneous malignant melanoma. Acta Pathol Microbiol Immunol Scand [A] 1985; 93: 4955.
  • 40
    McCarthy WH, Shaw HM, Milton GW. Efficacy of elective lymph node dissection. Surg Gynecol Obstet 1985; 161: 57580.